An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease

NCT00357786 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

NIH

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: Replagal agalsidase alfa
DRUG: Replagal

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)